Artivion (AORT)

The company reports through two main business areas: Medical Devices and Preservation Services. Medical Devices includes revenue from aortic stent graft systems, On-X heart valve products, surgical adhesives and sealants, and other cardiovascular devices. Preservation Services covers the processing and preservation of implantable human cardiac and vascular tissues, which are used by surgeons when biologic material is preferred or clinically required.

Artivion operates in North America, Europe, the Middle East and Africa, Latin America, and Asia-Pacific, with North America representing its largest revenue region. Its customer base is concentrated among hospitals, cardiovascular surgery centres, and specialist clinicians treating structural heart and vascular conditions.

What distinguishes Artivion is its aortic-centric strategy. Rather than competing broadly across all medical device categories, the company concentrates on technologies for aortic repair and cardiac reconstruction, including both synthetic and human tissue-based solutions. This gives it exposure to highly specialised procedures where product quality, surgeon familiarity, regulatory approvals, and clinical outcomes are central to adoption. The company was previously known as CryoLife, reflecting its long-standing involvement in preserved human tissue technologies.